Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GAVEL: Eganelisib, Venetoclax, and Azacitidine in Acute Myeloid Leukemia
NCT07439211Phase 1Recruiting
- Start
- Apr 2026
- Primary completion
- Feb 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of eganelisib in acute myeloid leukemia (AML) (2 arms). Primary endpoint: Recommended Phase 2 Dose at 28 days. Started Apr 2026; status: recruiting.
02
Drugs
eganelisib
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT07439211.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07439211.